Brief: Biosergen AB Says First Subject Dosed In Phase I Trial Of BSG005
07/04/2022 03:49
April 6 (Reuters) - Biosergen AB BIOSGN.ST :
* FIRST VOLUNTEER HAS BEEN DOSED WITH COMPANY'S PROPRIETARY
ANTIFUNGAL DRUG CANDIDATE BSG005
Source text for Eikon: ID:nWkrbW0dqQ
Further company coverage: BIOSGN.ST
((reuters.briefs@thomsonreuters.com;))
Recent news on Biosergen AB
See all newsBrief: Nasdaq Approves Biosergen's Delisting Application
Brief: Biosergen Applies For Delisting Of The Company's Shares From Nasdaq First North Growth Market Conditional Upon Completion Of The Merger With Flerie
Brief: Biosergen Resolves On Set-Off Issue
Brief: Biosergen Rights Issue Oversubscribed
Brief: Biosergen Reports H1 EBITDA Of SEK -10.5 Million